With sufficient royalties and sales-milestone payments on Ixifi, PFE could make more money from the two drugs combined than they can with Inflectra alone. Note that PFE has to share Inflectra profits with Celltrion.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.